Talk:Plasmin

Physiology Mid‑importance

	This article is within the scope of WikiProject Physiology, a collaborative effort to improve the coverage of Physiology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PhysiologyWikipedia:WikiProject PhysiologyTemplate:WikiProject PhysiologyPhysiology articles
Mid	This article has been rated as Mid-importance on the importance scale.
	This article has been classified as relating to blood.

Molecular Biology: MCB

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Molecular and Cell Biology task force (assessed as Low-importance).

Untitled[edit]

02:46, 11 November 2015 (UTC)172.78.62.6 (talk)Cite error: There are <ref> tags on this page without content in them (see the help page).==Plasminogen - Plasmin - Angiostatin == The article is called plasmin, but the template is about the gene product, plasminogen, and angiostatin, which is produced from plasmin, is not mentioned.. maybe the article needs some reogranization. --CopperKettle 14:31, 19 September 2009 (UTC)[reply]

Receptors[edit]

doi:10.1111/jth.12064 is a review about plasminogen receptors and their role in pathology. JFW | T@lk 17:03, 30 January 2013 (UTC)[reply]

Interactions[edit]

TRANEXAMIC ACID (LYSTEDA) is a new drug approved by the FDA to treat cyclic heavy menstrual bleeding and its mechanism of action is to prevent plasminogen conversion to plasmin. It therefore acts as a antifibrinolytic. Marketing ads tout this as a non-hormonal way to treat cyclic heavy menstrual bleeding but it poses serious risks of blood clots, especially in women using hormonal contraceptives, and for this reason it is contraindicated in that group.

http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf